Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. by Chung, J. et al.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 5 7 4 jci.org   Volume 127   Number 4   April 2017
Introduction
Allogeneic bone marrow transplantation (allo-BMT) can cure 
hematological malignancies and other blood disorders. However, 
alloimmune T cell responses arising against foreign tissue antigens 
can trigger major complications such as graft-versus-host disease 
(GVHD) after allo-BMT (1–3). At the onset of GVHD, donor T cells 
are exposed to host tissue alloantigens in a highly inflammatory 
environment, inducing potent T cell immunoreactivity and subse-
quent pathogenicity. Current GVHD prophylactic and therapeutic 
strategies act through global immunosuppression and thus dimin-
ish both beneficial and detrimental aspects of T cell alloreactivity. 
Efforts to develop new selective therapies to dampen GVHD have 
focused on early microenvironmental signals to donor alloreac-
tive T cells (4). Many of these signals, which include alloantigens, 
costimulatory ligands, and local inflammatory mediators, have 
been assumed to derive from hematopoietic antigen-presenting 
cells (APCs) (5–7). However, recent work demonstrated that CD4+ 
T cell–mediated alloresponses can occur in the absence of hema-
topoietic APCs as a source of alloantigens (8–10), suggesting that 
our current understanding of key early cellular and molecular 
events that drive donor T cell–mediated GVHD is incomplete.
The Notch pathway has emerged as a new, attractive thera-
peutic target to control the deleterious effects of T cell alloimmu-
nity (11–17). Notch signaling is a conserved cell-to-cell commu-
nication pathway mediated by interactions between NOTCH1-4 
receptors and their ligands Delta-like 1/3/4 (DLL1/3/4) or JAG-
GED1/2 (JAG1/2) (18, 19). During GVHD, DLL1/4 ligands in the 
host engage NOTCH1/2 receptors in T cells, and transient sys-
temic blockade of DLL1/4 Notch ligands with neutralizing anti-
bodies results in long-term protection from GVHD (14). Despite 
the central role of Notch signaling in alloreactivity, the timing of 
critical Notch signals, the cellular source of Notch ligands, and the 
Alloimmune T cell responses induce graft-versus-host disease (GVHD), a serious complication of allogeneic bone marrow 
transplantation (allo-BMT). Although Notch signaling mediated by Delta-like 1/4 (DLL1/4) Notch ligands has emerged as 
a major regulator of GVHD pathogenesis, little is known about the timing of essential Notch signals and the cellular source 
of Notch ligands after allo-BMT. Here, we have shown that critical DLL1/4-mediated Notch signals are delivered to donor 
T cells during a short 48-hour window after transplantation in a mouse allo-BMT model. Stromal, but not hematopoietic, 
cells were the essential source of Notch ligands during in vivo priming of alloreactive T cells. GVHD could be prevented 
by selective inactivation of Dll1 and Dll4 in subsets of fibroblastic stromal cells that were derived from chemokine Ccl19-
expressing host cells, including fibroblastic reticular cells and follicular dendritic cells. However, neither T cell recruitment 
into secondary lymphoid organs nor initial T cell activation was affected by Dll1/4 loss. Thus, we have uncovered a 
pathogenic function for fibroblastic stromal cells in alloimmune reactivity that can be dissociated from their homeostatic 
functions. Our results reveal what we believe to be a previously unrecognized Notch-mediated immunopathogenic role for 
stromal cell niches in secondary lymphoid organs after allo-BMT and define a framework of early cellular and molecular 
interactions that regulate T cell alloimmunity.
Fibroblastic niches prime T cell alloimmunity through 
Delta-like Notch ligands
Jooho Chung,1,2 Christen L. Ebens,2,3,4 Eric Perkey,1,2 Vedran Radojcic,2,5 Ute Koch,6 Leonardo Scarpellino,7 Alexander Tong,8 
Frederick Allen,8 Sherri Wood,9 Jiane Feng,9 Ann Friedman,2 David Granadier,2 Ivy T. Tran,2 Qian Chai,10 Lucas Onder,10  
Minhong Yan,11 Pavan Reddy,5 Bruce R. Blazar,4 Alex Y. Huang,8 Todd V. Brennan,12 D. Keith Bishop,9 Burkhard Ludewig,10 
Christian W. Siebel,11 Freddy Radtke,6 Sanjiv A. Luther,7 and Ivan Maillard2,5
1Graduate Program in Cellular and Molecular Biology, 2Life Sciences Institute, and 3Division of Hematology-Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.  
4Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA. 5Division of Hematology-Oncology, Department of Internal Medicine, 
University of Michigan, Ann Arbor, Michigan, USA. 6École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. 7Department of Biochemistry, University of Lausanne, Epalinges, Switzerland. 
8Medical Scientist Training Program and Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA. 9Department of Surgery, University  
of Michigan, Ann Arbor, Michigan, USA. 10Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 11Genentech, South San Francisco, California, USA. 12Department of Surgery,  
Duke University, Durham, North Carolina, USA.
     Related Commentary: p. 1215
Authorship note: J. Chung and C.L. Ebens contributed equally to this work.
Note regarding evaluation of this manuscript: Manuscripts authored by scientists 
associated with Duke University, The University of North Carolina at Chapel Hill, 
Duke-NUS, and the Sanford-Burnham Medical Research Institute are handled not by 
members of the editorial board but rather by the science editors, who consult with 
selected external editors and reviewers.
Conflict of interest: M. Yan and C.W. Siebel are employed by Genentech.
Submitted: July 12, 2016; Accepted: January 5, 2017.
Reference information: J Clin Invest. 2017;127(4):1574–1588. 
https://doi.org/10.1172/JCI89535.
Downloaded from http://www.jci.org on April 19, 2017.   https://doi.org/10.1172/JCI89535
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 5 7 5jci.org   Volume 127   Number 4   April 2017
as nonredundant sources of DLL1-mediated Notch signals to mar-
ginal-zone B cells and DCs that express high levels of endothelial 
cell–specific adhesion molecule high (ESAMhi DCs), as well as of 
DLL4-mediated signals to follicular helper T cells (32). Thus, mul-
tiple cellular sources have the potential to deliver Notch signals to 
T cells in vivo after allo-BMT, making it unclear whether critical 
signals are delivered in a defined microanatomical niche, and by 
hematopoietic or stromal cells.
To address these questions, we used a combination of systemic 
neutralizing antibodies and loss-of-function genetics to interrogate 
the in vivo spatial and temporal requirements for DLL1/4-mediated 
Notch signaling during GVHD. Surprisingly, we found that essen-
tial Notch signals were delivered to incoming T cells within 2 days 
of allo-BMT and that both donor and host hematopoietic cells were 
dispensable as a source of Notch ligands driving acute GVHD. In 
contrast, we found that subsets of nonhematopoietic fibroblastic 
stromal cells lineage traced with a Ccl19-Cre transgene functioned 
as the essential cellular source of Delta-like Notch ligands after 
allo-BMT. Interference with Notch ligands in fibroblastic stromal 
cells had selective effects on T cell alloreactivity and did not impair 
other functions of these cells in immune homeostasis. These find-
ings change our understanding of the key early cellular and molec-
microanatomical context in which alloreactive T cells are exposed 
to Notch signaling in vivo remain unknown.
Early studies showed that hematopoietic APCs such as DCs 
can express DLL1 and DLL4 ligands in a TLR-inducible manner 
(20, 21). These observations led to the widely accepted concept 
that hematopoietic APCs can simultaneously deliver antigen and 
Notch ligands to modulate T cell function. In vitro studies sup-
ported this model, as TLR agonist–stimulated antigen-pulsed DCs 
induced naive T cells to differentiate in a Notch-regulated manner 
(21, 22). Similarly, a subpopulation of CD11c+DLL4hi DCs was capa-
ble of delivering Notch signals to alloreactive T cells in mixed lym-
phocyte reactions when purified from GVHD animal models (23). 
However, the in vivo relevance of APC-derived Notch signals has 
not been rigorously tested, and their importance has been inferred 
indirectly on the basis of their capacity to modulate T cell respons-
es in vitro. Nonhematopoietic cells also express Notch ligands in 
multiple contexts, including in primary and secondary lymphoid 
organs (SLOs). In the thymus, FOXN1+ thymic epithelial cells act 
as nonredundant transducers of DLL4-mediated signals during T 
cell development (24–26). Blood and lymphatic endothelial cells 
(BECs and LECs) express high levels of DLL1 and DLL4 (27–31). 
Finally, genetic studies identified fibroblastic stromal cells in SLOs 
Figure 1. An early pulse of Notch signaling is critical to drive pathogenic T cell alloreactivity after BMT. (A) Dosing schedule of systemic neutralizing anti-
bodies against DLL1 and DLL4 Notch ligands. (B) Survival, GVHD score, and weight of lethally irradiated (8.5 Gy) BALB/c mice transplanted with 5 × 106 T cell–
depleted (TCD) B6 BM or 5 × 106 TCD B6 BM plus 5 × 106 allogeneic B6 splenocytes. Isotype control versus anti-DLL1/4 antibodies were injected i.p., as shown 
in A (n = 10 mice/group). (C) Intracellular cytokine production by donor CD4+ T cells after anti-CD3/CD28 restimulation on day 6 after transplantation (n = 5 
mice/group). (D) Intracellular FoxP3 in donor CD4+ T cells on day 6 (n = 5 mice/group). *P < 0.05, **P < 0.01, ***P < 0.001, and NS = P > 0.05, by unpaired, 
2-tailed Student’s t test with Sidak’s correction for multiple comparisons. Data are representative of at least 4 experiments; error bars indicate SD.
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JCI89535DS1). In contrast, delayed initiation of antibody treat-
ment by only 2 days resulted in loss of clinical protection, per-
sistent IFN-γ and TNF-α production, and no increase in Treg num-
bers. DLL1/4 blockade inhibited cytokine production and Notch 
target gene expression in T cells recovered from both spleens and 
lymph nodes (LNs) (Supplemental Figure 1, B and C). Notch tar-
get gene expression was decreased in proliferating donor-derived 
alloreactive T cells isolated during the temporal window of Notch 
sensitivity (Supplemental Figure 1, D and E). These data identify 
an early pulse of Notch signaling delivered within 2 days of allo-
BMT that programs T cells to a pathogenic state of reactivity.
Donor and host hematopoietic cells are dispensable sources of Notch 
ligands during GVHD. The early window of sensitivity to Notch 
inhibition suggested that T cells might receive Notch signals from 
residual host hematopoietic APCs, which can express both alloan-
tigens and Notch ligands (21–23, 33–35). To test whether hemato-
poietic APCs were responsible for delivering Notch signals to donor 
alloreactive T cells, we generated BM chimeras lacking DLL1/4 
ular events that condition the outcome of T cell alloimmunity. In 
addition, they pave the way toward the development of targeted 
therapeutic approaches to block Notch signaling and other stro-
mal niche–derived pathogenic signals in GVHD and other T cell–
mediated immune disorders.
Results
Early DLL1/4-mediated Notch signals drive T cell alloreactivity 
during acute GVHD. To understand the temporal requirement for 
Notch signaling after allo-BMT, we used neutralizing antibodies 
against DLL1 and DLL4 Notch ligands in an irradiation-dependent 
MHC-mismatched mouse allo-BMT model (Figure 1A). A single 
injection of DLL1- and DLL4-neutralizing antibodies before allo-
BMT was sufficient for long-term protection from GVHD lethality 
and morbidity, decreased production of T cell proinflammatory 
cytokines by CD4+ and CD8+ T cells, and expanded FoxP3+ Tregs 
(Figure 1, B–D, Supplemental Figure 1A; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
Figure 2. Host hematopoietic cells are dispensable as cellular sources of DLL1/4 Notch ligands in acute GVHD. (A) Experimental strategy. BM chime-
ras were generated via transplantation of syngeneic B6-CD45.2+ poly(I:C)-induced TgMx1-Cre– littermate control or TgMx1-Cre+ Dll1Δ/Δ Dll4Δ/Δ BM into irradiated 
B6-CD45.1 recipients. After reestablishment of steady-state hematopoiesis 12 weeks later, BM chimeras were subjected to a second syngeneic or alloge-
neic transplant, with or without systemic anti-DLL1/4 blockade. (B) Quantification of Dll1 and Dll4 inactivation in sort-purified Gr1+CD11b+ blood myeloid 
cells from BM chimeras 12 weeks after transplantation (PCR). In this particular experiment, control BM chimeras were generated from poly(I:C)-induced 
TgMx1-Cre– Dll1fl/+ Dll4fl/+ donor mice. Each lane represents an individual mouse. (C) Donor chimerism (frequency of CD45.2+ donor cells) in the indicated splenic 
cell populations 12 weeks after transplantation. MΦ, macrophages; pDCs, plasmacytoid DCs. (D) Survival and weight loss of lethally irradiated (11 Gy) BM 
chimeras transplanted with 8 × 106 TCD BM plus 30 × 106 B6 splenocytes (syngeneic control) or 30 × 106 allogeneic BALB/c splenocytes (allo-BMT). Isotype 
control or anti-DLL1/4 antibodies were injected i.p. on days 0, 3, 7, and 10 (n = 10 mice/group). (E) Abundance of Dtx1 Notch target gene transcripts (qRT-
PCR) in sort-purified donor CD4+ T cells and CD8+ cells on day 6 (n = 5 mice/group). *P < 0.05, **P < 0.01, and NS = P > 0.05, by unpaired, 2-tailed Student’s 
t test with Sidak’s correction for multiple comparisons. Data are representative of at least 2 experiments; error bars indicate SD.
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derived T cells expressed equivalent amounts of Notch target gene 
transcripts in Dll1Δ/Δ Dll4Δ/Δ→B6-CD45.1 and control chimeras, but 
transcript abundance remained sensitive to systemic anti-DLL1/4 
antibodies (Figure 2E). Thus, host hematopoietic cells were dis-
pensable as a source of Notch ligands after allo-BMT.
To rule out redundant DLL1/4 expression in donor and host 
hematopoietic cells, we backcrossed TgMx1–Cre+ Dll1fl/fl Dll4fl/fl mice 
onto the BALB/c background and generated BM chimeras with 
poly(I:C)-induced TgMx1–Cre+ Dll1Δ/Δ Dll4Δ/Δ donors (Dll1Δ/Δ Dll4Δ/Δ→ 
BALB/c) (Supplemental Figure 2A). Transplantation of Dll1Δ/Δ 
only in hematopoietic cells with poly(I:C)-induced TgMx1-Cre+ Dll1Δ/Δ 
Dll4Δ/Δ BM (designated as Dll1Δ/Δ Dll4Δ/Δ→B6-CD45.1) (Figure 2A). 
This strategy led to efficient Cre-mediated recombination and high 
donor chimerism in all hematopoietic APCs (Figure 2, B and C). 
Allo-BMT into Dll1Δ/Δ Dll4Δ/Δ→B6-CD45.1 chimeras as compared 
with control BM chimeras did not protect mice from GVHD mor-
tality or morbidity (Figure 2D). In contrast, systemic antibody-me-
diated DLL1/DLL4 blockade protected both Dll1Δ/Δ Dll4Δ/Δ→B6-
CD45.1 and control BM chimeras from GVHD lethality. Consistent 
with persistent exposure to DLL1/4 ligands in these mice, donor- 
Figure 3. Ccl19-Cre+ lineage–traced stromal cells are the critical cellular source of 
DLL1/4 Notch ligands during acute GVHD. (A) LNs were collected on day 1.5 after trans-
plantation from lethally irradiated TgCcl19-Cre+ ROSA26eYFP mice receiving allogeneic BALB/c 
splenocytes and enzymatically digested. (A, top) eYFP expression in LN-resident bulk 
fibroblastic stromal cells (PDPN+CD31–) as well as subfractionated CD157+ FRCs, CD157– 
FRCs, and CD21+ FDCs. (A, middle) eYFP in LECs, BECs, PDPN–CD31– stromal cells (DNs). 
(A, bottom) eYFP in macrophages, conventional DCs (cDCs), pDCs, and skin-derived 
Langerhans cells. Bars in histograms define gating for eYFP+ cells, and numbers indicate 
the percentage of gated eYFP+ cells within parental cell populations, as identified by 
flow cytometric analysis. Bar graph in A shows the mean percentage of eYFP expression 
in each indicated nonhematopoietic subset (n = 4 mice/group; error bars indicate SD). 
(B) Survival, GVHD score, and weight of lethally irradiated (12 Gy) littermate control 
TgCcl19-Cre– or TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice that were transplanted with 10 × 106 TCD BM only 
or 10 × 106 TCD BM plus 20 × 106 allogeneic BALB/c splenocytes. Isotype control or anti-
DLL1/4–neutralizing antibodies were injected i.p. on days 0, 3, 7, and 10 (n = 10 mice/
group). (C) Intracellular cytokines in donor CD4+ cells after anti-CD3/CD28 restimulation 
on day 6 (n = 5 mice/group). (D) Relative abundance of Dtx1 and Hes1 Notch target gene 
transcripts in donor CD4+ T cells sort purified from TgCcl19-Cre– plus isotype control, TgCcl19-Cre– 
plus anti-DLL1/4, or TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ recipient mice on day 2 after transplantation 
(n = 5 mice/group). *P < 0.05, **P < 0.01, and ***P < 0.001, by unpaired, 2-tailed Stu-
dent’s t test with Sidak’s correction for multiple comparisons. Data are representative 
of at least 5 experiments; error bars indicate SD.
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also lineage traced a smaller fraction of PDPN+CD31+ LECs and 
very few PDPN–CD31– stromal cells. In contrast, TgCcl19–Cre was inac-
tive in PDPN–CD31+ BECs and in all hematopoietic cells, includ-
ing professional APCs in SLOs and Langerhans cells isolated from 
the epidermis (Figure 3A and Supplemental Figure 3, A–D). Thus, 
TgCcl19-Cre had a pattern of activity suitable for inactivation of Dll1/4 
selectively in subsets of fibroblastic stromal cells (including FRCs 
and FDCs) and in a small fraction of LECs.
TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice were highly protected from 
GVHD lethality and morbidity (Figure 3B). Markedly fewer donor 
T cells from TgCcl19-Cre+ Dll1Δ/ΔDll4Δ/Δ recipients produced proinflam-
matory cytokines, as observed with systemic DLL1/4 blockade 
(Figure 3C and Supplemental Figure 4). Notch target gene tran-
scripts were profoundly decreased in donor-derived T cells isolat-
ed from TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ recipients (Figure 3D). As shown 
with anti-DLL1/4 antibodies (Supplemental Figure 1, B and C), 
the effects of Ccl19-Cre–mediated Dll1/4 loss were observed in the 
spleen (which lacks LECs) as well as in LNs (Figure 3, C and D, and 
data not shown). Thus, nonhematopoietic cells lineage traced by 
Ccl19-Cre were the dominant source of DLL1/DLL4 Notch ligands 
encountered in vivo by donor T cells after allo-BMT.
T cell cytokine production was preserved after allo-BMT into 
TgCcl19–Cre+ Dll1+/+ Dll4+/+ control recipients, ruling out Cre toxici-
ty (Supplemental Figure 5). To assess whether DLL1/4 blockade 
Dll4Δ/Δ→B6-CD45.1 donor cells into Dll1Δ/Δ Dll4Δ/Δ→BALB/c recipi-
ents (designated as Dll1Δ/Δ Dll4Δ/Δ→Dll1Δ/Δ Dll4Δ/Δ) had no impact on 
T cell cytokine production or Treg frequencies (Supplemental Fig-
ure 2, B–D), despite sensitivity to systemic DLL1/DLL4 blockade. 
Donor-derived T cells from Dll1Δ/Δ Dll4Δ/Δ→Dll1Δ/Δ Dll4Δ/Δ recipient 
mice retained abundant Notch target gene transcripts (Supplemen-
tal Figure 2E). Therefore, both donor and host hematopoietic cells 
were dispensable sources of DLL1/4 Notch ligands during GVHD.
Ccl19-Cre+ stromal cells are critical sources of Notch ligands during 
GVHD. Among multiple radioresistant nonhematopoietic cells that 
express Notch ligands in SLOs, fibroblastic stromal cells lineage 
traced with Ccl19-Cre act as a non-motile source of Notch ligands to 
immune cells in steady-state conditions (32). To assess the impor-
tance of these cells during allo-BMT, we conditionally inactivated 
Dll1 and Dll4 with Ccl19-Cre (hereafter referred to as TgCcl19-Cre+ Dll1Δ/Δ 
Dll4Δ/Δ) (36–38). After irradiation and allo-BMT, lineage tracing by 
Ccl19-Cre was detected in PDPN+CD31– fibroblastic stromal cells, 
as assessed by Cre-inducible enhanced yellow fluorescent protein 
(eYFP) expression from a ROSA26eYFP allele (Figure 3A and Supple-
mental Figure 3A). Further characterization of Ccl19-Cre activity 
within cellular subsets of PDPN+CD31– stromal cells showed eYFP 
in more than 95% of cells from the CD157hiCD21– subset (consistent 
with fibroblastic reticular cells [FRCs]) and from the CD157hiCD21+ 
subset (consistent with follicular dendritic cells [FDCs]). TgCcl19-Cre 
Figure 4. Ccl19-Cre–mediated Dll1 and Dll4 inactivation preserves lymphocyte numbers and distribution in SLOs at steady state. (A) Absolute numbers 
of CD4+ T cells, CD8+ T cells, and B cells in spleens and LNs of B6 littermate control TgCcl19-Cre– or TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice at steady state (n = 5 mice/
group). (B and C) CD62L and CD44 expression in CD4+ (B) and CD8+ (C) T cells from spleens and LNs of TgCcl19-Cre– or TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice at steady 
state. (D) Abundance of Il7 transcripts (qRT-PCR) in sort-purified PDPN+CD31– fibroblastic stromal cells from TgCcl19-Cre– or TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice (n = 5 
mice/group). NS = P > 0.05, by unpaired, 2-tailed Student’s t test. Data are representative of at least 3 experiments; error bars indicate SD.
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might impact GVHD through effects that are independent of 
T cells, we established an experimental system that preserved 
stroma-derived Notch signals in T cells, but removed Notch- 
dependent non–T cells. Past work showed that NOTCH2 receptors 
engaged by stromal DLL1/4 ligands control the development and/
or maintenance of ESAMhi DCs, CD8+ DCs, and marginal-zone B 
cells in the spleen (39–41). We generated syngeneic BM chime-
ras using poly(I:C)-induced TgMx1-Cre+ Notch2Δ/Δ or control TgMx1-Cre– 
Notch2fl/fl progenitors (Supplemental Figure 6A). These BM chi-
meras lacked marginal-zone B cells and had decreased numbers 
of NOTCH2-dependent CD8+ and ESAMhi DCs, as expected 
(Supplemental Figure 6B and refs. 39–41). We subjected these 
BM chimeras to allogeneic BMT with MHC-mismatched BALB/c 
BM and purified T cells. With this approach, recipient mice lacked 
NOTCH2-dependent host populations but had preserved stromal 
DLL1/4 expression (Supplemental Figure 6, A, C, and D). Sys-
temic DLL1/4 inhibition blocked the production of IL-2, IFN-γ, 
and TNF-α by donor-derived T cells after allo-BMT. In contrast, 
TgMx1-Cre+ Notch2Δ/Δ chimeras showed preserved cytokine pro-
duction in LNs and increased, but not decreased, production in 
donor-derived splenic T cells. These findings indicate that loss of 
NOTCH2-dependent host splenic cells cannot indirectly explain 
the impact of DLL1/4 inhibition during GVHD, which is consistent 
with the observed direct effects of DLL1/4 on donor T cells.
Figure 5. Ccl19-Cre–mediated Dll1 and Dll4 inactivation does not impair T cell recruitment or proliferation in SLOs after irradiation, but selectively 
affects Notch target gene transcripts. (A–E) Absolute numbers (A), proliferation (CFSE dilution) on day 2.5 (B) versus day 6 after transplantation (C), and 
expression of activation markers. Bars in histograms define gating for proliferated CFSElow and unproliferated CFSEhi cells, and numbers indicate the per-
centage of gated cells among parental cell populations, as identified by flow cytometric analysis. Bar graphs represent the mean percentage of proliferated 
(CFSElow) cells in each population (n=5 mice/group); error bars indicate SD. (D and E) by donor-derived CD4+ and CD8+ T cells after transplantation into 
lethally irradiated (12 Gy) littermate control TgCcl19-Cre– or TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ B6 recipient mice. Donor cells were isolated on day 2.5 or day 6 after trans-
plantation (n = 5 mice/group). (F) Abundance of the indicated transcripts (qRT-PCR) in sort-purified donor-derived CFSEdiluted BALB/c CD4+ T cells on day 2 
after transplantation into irradiated B6 hosts treated with or without anti-DLL1/4 antibodies. *P < 0.05, **P < 0.01, NS = P > 0.05, by unpaired, 2-tailed 
Student’s t test. Data are representative of at least 3 experiments; error bars indicate SD. MFI, mean fluorescence intensity.
Downloaded from http://www.jci.org on April 19, 2017.   https://doi.org/10.1172/JCI89535
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 5 8 0 jci.org   Volume 127   Number 4   April 2017
Figure 6. Irradiation changes the LN ultrastructure and increases the relative density of Ccl19-Cre+ stromal cells. (A) Total cellularity, absolute numbers 
of CD45+ cells, and absolute numbers and frequencies of eYFP+ cells in LNs of unirradiated or lethally irradiated (12 Gy) TgCcl19-Cre+ ROSA26eYFP reporter mice 
receiving allogeneic BALB/c splenocytes (n = 6 mice/group). **P < 0.01, ***P < 0.001, NS = P > 0.05, by unpaired, 2-tailed Student’s t test. (B) Immunoflu-
orescence microscopy images of LN cryosections from TgCcl19-Cre+ ROSA26eYFP mice stained for GFP. Cryosections were from unirradiated or lethally irradiated 
(12 Gy) mice receiving no T cells, syngeneic B6 CD4+ T cells, or allogeneic BALB/c CD4+ T cells. (C and D) Immunofluorescence microscopy images of LN cryo-
sections from TgCcl19-Cre+ ROSA26eYFP mice stained for B220 and CD3 (C, top panel); eYFP, CD11b, and CD169 (C, bottom panel); eYFP and PDPN (D, top panel); 
and eYFP and CD35 (D, bottom panel). Cryosections were from unirradiated or lethally irradiated (12 Gy) mice receiving allogeneic BALB/c CD4+ T cells on 
day 1.5 after transplantation. Data are representative of 2 experiments.
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tribbles pseudokinase 2 (Trib2), and hairy and enhancer of split 1 
(Hes1) in donor CD4+ T cells (Figure 5F). However, phosphatase 
and tensin homolog (Pten) mRNA was unchanged, indicating that 
Hes1-mediated Pten repression did not operate in alloreactive T 
cells (52, 53). Other genes, including Myc, that were previously 
identified as Notch transcriptional targets in T cell acute lympho-
blastic leukemia were expressed at normal levels (Figure 5F and 
refs. 54, 55). Altogether, DLL1/4 loss in FRCs maintained T cell 
recruitment and initial activation, which is consistent with our 
observation of preserved classical FRC functions but selective loss 
of DLL1/4-mediated instructive signals to incoming T cells.
Irradiation rapidly alters the microanatomy of SLOs. To assess 
the impact of allo-BMT on SLO organization with respect to Ccl19-
Cre+ fibroblastic stromal cells, we studied TgCcl19-Cre+ ROSA26eYFP 
mice. We found that allo-BMT reduced LN cellularity due to loss 
of radiosensitive hematopoietic cells, while absolute numbers of 
eYFP+ cells were preserved (Figure 6A). Flow cytometric anal-
ysis and immunofluorescence microscopy revealed markedly 
increased relative frequencies of eYFP+ stromal cells in LN and 
spleen after allo-BMT (Figure 6, A and B, and Supplemental Fig-
ure 7A), concomitant with depletion of radiosensitive lymphocytes 
and thickening of the subcapsular macrophage layer (Figure 6C 
and Supplemental Figure 7B). eYFP+ fibroblastic cells from allo-
BMT mice were located within both the T zone and B follicles, as 
Genetic inactivation of DLL1/4 ligands within Ccl19-Cre+ stro-
mal cells preserves immune homeostasis and classical functions of 
FRCs. Among fibroblastic stromal cells, FRCs provide survival 
and migration cues to naive T cells (42), form conduits for anti-
gen trafficking (43), and support the overall SLO infrastructure 
(37, 44–48). Physical loss of FRCs disrupts immune homeostasis, 
leading to profoundly impaired immune responses (37). To deter-
mine whether these FRC functions were preserved in TgCcl19-Cre+ 
Dll1Δ/Δ Dll4Δ/Δ mice, we studied these mice during steady state 
and in the peri-transplantation period. SLOs from nonirradiated 
TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice had normal lymphocyte numbers, 
naive/memory T cell distribution, and Il7 expression in FRCs (Fig-
ure 4, A–D). After allo-BMT, normal numbers of donor T cells were 
recovered upon Dll1/4 inactivation in FRCs and showed no impact 
on T cell homing or survival (Figure 5A). Donor T cell prolifera-
tion was maintained in TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ recipients (Figure 
5, B and C), or was only mildly decreased at early time points for 
CD4+ T cells (Figure 5B). Donor CD4+ and CD8+ T cells normal-
ly upregulated the early activation markers CD44 (Figure 5, D 
and E) and CD69 (not shown). CD25 was decreased in TgCcl19-Cre+ 
Dll1Δ/Δ Dll4Δ/Δ hosts (Figure 5, D and E), consistent with reports 
that Notch can regulate IL-2 receptor subunit α (Il2ra) expression 
in T cells (49–51). We also observed a decreased abundance of the 
Notch target gene transcripts deltex 1, E3 ubiquitin ligase (Dtx1), 
Figure 7. DLL4 expression within different LN nonhematopoietic cell populations after allogeneic BMT. (A) LN stromal cell subsets. TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ 
and TgCcl19-Cre– littermate control mice were lethally irradiated before infusion of allogeneic BALB/c splenocytes. LNs were collected on day 1.5 after trans-
plantation and enzymatically digested. Dot plots show representative flow cytometric analysis of CD45–Ter119– nonhematopoietic stromal cells. (B) DLL4 
expression in LN-resident nonhematopoietic cell subsets. Roman numerals refer to the cell populations shown in A. (C) MFI comparing DLL4 expression 
in stromal cell subsets from TgCcl19-Cre– versus TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice as well as isotype staining in controls. **P < 0.01 and ***P < 0.001, by unpaired 
2-tailed Student’s t test with Sidak’s correction for multiple comparisons. (D) Representative flow cytometric plots of PDPN+CD31–CD21/35– FRCs showing 
DLL4 expression in the CD157hi subset. Data are representative of at least 3 experiments.
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Defined fibroblastic niches deliver Notch ligands to donor alloreac-
tive T cells. We next investigated the distribution of Notch ligands 
in SLOs after allo-BMT, focusing on DLL4, since it is the dominant 
Notch ligand driving GVHD (14). We examined cell-surface DLL4 
within 6 distinct populations of Ter119–CD45– LN stromal cells, as 
defined by expression of CD31, PDPN, CD157/BP3, and CD21/35 
(Figure 7). Comparison of control TgCcl19-Cre– and TgCcl19-Cre+ Dll1Δ/Δ 
Dll4Δ/Δ mice identified cellular subsets expressing functionally rele-
vant Notch ligands after allo-BMT. Interestingly, DLL4 expression 
was not uniformly distributed among all Ccl19-Cre+ stromal cells, 
but was observed in a fraction of PDPN+CD31– FRCs marked by 
delineated by the stromal markers podoplanin (PDPN) and CD35, 
respectively. T zone Ccl19-Cre+ fibroblastic cells showed increased 
staining intensity for PDPN, while CD35, CD157/BP3, and muco-
sal vascular addressin cell adhesion molecule 1 (MAdCAM-1) 
staining of stromal cells in B follicles was also highly apparent 
(Figure 6D and Supplemental Figure 7C). The increased staining 
intensity could be related at least in part to the rise in stromal cell 
density within a given surface area after irradiation (Figure 6B). 
Thus, allo-BMT rapidly altered the spatial organization of lym-
phoid organ–resident cells, exposing donor T cells to a dense net-
work of stromal cells.
Figure 8. Fibroblastic niches in spleen express DLL1/4 Notch ligands and localize next to alloreactive T cells. (A and B) Immunofluorescence microscopy 
of splenic cryosections from TgCcl19-Cre+ Dll1+/+ Dll4+/+ ROSA26eYFP and TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ ROSA26eYFP mice stained for GFP, CD35, and DLL4 (A) or GFP, CD157, 
and DLL4 (B). (C–E) Immunofluorescence microscopy of splenic cryosections from lethally irradiated (8.5 Gy) BALB/c mice transplanted with CMTMR- 
labeled alloantigen-specific CD4+ 4C TCR–transgenic cells and pulsed with EdU 12 hours prior to organ collection to label proliferating cells. Cryosections 
were incubated with Alexa Fluor 488 picolyl azide to reveal EdU, along with anti-DLL4 (C), anti-CD35 (D), or anti-CD157 (E). Organs were collected on day 1.5 
after transplantation. Data are representative of at least 2 experiments.
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in concert with inflammatory signals from the microenvironment, 
are thought to provide essential instructive signals to induce T cell 
alloreactivity. Our findings revise this prevailing model of GVHD 
pathogenesis, as they identify LN- and spleen-resident Ccl19-Cre+ 
fate-mapped stromal cells as key initiators of alloimmune T cell 
pathogenicity through induction of Notch signals in donor-derived 
T cells. Contrary to past assumptions, donor and host hematopoi-
etic APCs were not responsible for the delivery of Notch signals to 
donor T cells, as genetic inactivation of Delta-like Notch ligands 
within donor and host hematopoietic APCs failed to ameliorate 
GVHD. In contrast, selective inactivation of Notch ligands within 
stromal cells derived from Ccl19-Cre–expressing cells resulted in 
long-term protection from GVHD. Thus, specialized stromal nich-
es are uniquely important in the context of alloimmunity.
In this study, several populations of stromal cells were lineage 
traced by Ccl19-Cre and should, given our findings, be considered 
potential essential sources of DLL1/4 Notch ligands available 
to alloreactive T cells at the onset of GVHD. Our findings identi-
fy spleen and LN fibroblastic stromal cells expressing high levels 
of PDPN and CD157 as prime candidates for sources of DLL1/4 
Notch ligands. These DLL4-expressing fibroblasts are referred to 
as FRCs and are thought to reside predominantly in the T cell zone 
of SLOs. In addition, we detected high DLL4 expression in stromal 
cells with characteristics of FDCs. Although these cells are locat-
ed within follicles that are not typically entered by naive T cells, 
post-irradiation changes may change trafficking rules in SLOs and 
render FDCs accessible to incoming alloreactive T cells, reminis-
cent of T follicular helper cells and memory CD8+ T cells (57). The 
small fraction of LECs lineage traced by Ccl19-Cre also represents 
a potential source of Notch ligands in LNs. However, we observed 
prominent DLL1/4-dependent effects on alloreactive T cells locat-
ed in the spleen, even during the early peri-transplantation period, 
when T cell recirculation is unlikely. As the spleen contains hard-
ly any LECs, these cells are unlikely to be the dominant source of 
DLL1/4 ligands in GVHD. We observed no DLL4 expression in red 
pulp cells, where very little Ccl19-Cre activity was detected. Aside 
from its activity in the spleen and LNs, Ccl19-Cre is also active in 
fibroblastic cell subsets from Peyer’s patches (58). Thus, Peyer’s 
patches and other gut-associated lymphoid structures could also be 
sites of DLL1/4-mediated Notch activation in T cells during GVHD.
Immunofluorescence microscopy and flow cytometric anal-
ysis of SLOs after allo-BMT demonstrated that Delta-like Notch 
ligand expression was not uniformly distributed throughout all 
fibroblastic stromal cells of the lymphoid compartment. Instead, 
we observed focal niches of Notch ligand expression within 
Ccl19-Cre+ cells marked by the stromal surface markers CD157 
and CD21/35. Concomitant expression of chemokines and Del-
ta-like Notch ligands in resident nonhematopoietic cells within 
defined SLO niches bears similarities to the coregulated expres-
sion of chemokines and DLL4 ligands in cortical thymic epithelial 
cells. In the thymus, Foxn1 controls expression of CCL21/25 and 
DLL4, which is critical to attract lymphoid progenitors and induce 
T lineage development (26). We speculate that SLOs rely on a 
similar organizational module to attract immune cells to defined 
niches with specialized immunological functions in which they 
are exposed to Notch ligands and other regulatory signals. This 
is consistent with the role of fibroblastic stromal cells as a source 
high levels of CD157/BP3, and in PDPN+CD31–CD21/35hi cells that 
were immunophenotypically consistent with FDCs. In keeping with 
the capacity of Ccl19-Cre to lineage trace the majority of CD157hi 
FRCs and FDCs (Figure 3A), DLL4 expression was reduced to iso-
type control levels in these cell populations. LECs expressed slight-
ly decreased levels of DLL4 in TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice, consis-
tent with the Ccl19-Cre activity we observed in a small fraction of 
LECs (Figure 3A). We found that PDPN+CD31–CD157lo FRCs had 
no detectable DLL4, while BECs expressed DLL4 in both control 
and TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice (Figure 7).
In the spleen, characterization of stromal cells by flow cytom-
etry is more challenging than in LNs due to difficulties in isola-
tion and the presence of many red pulp fibroblasts (39). TgCcl19-Cre 
expression induced ROSA26-eYFP expression in a high proportion 
of PDPN+CD31–CD157hi and PDPN+CD31–CD21/35hi stromal cells 
that were phenotypically similar to their LN counterparts (Supple-
mental Figure 8, A and B). Histological evaluation revealed that 
these cells were restricted to the white pulp cords and most likely 
represented T zone FRCs and B zone FDCs (Supplemental Figure 
7, A–C). Both cell populations expressed surface DLL4 that was 
abrogated by Ccl19-Cre–mediated Dll4 inactivation (Supplemen-
tal Figure 8C). eYFP was also detected in fewer than 10% of the 
rare PDPN+CD31–CD157lo cells and in fewer than 2% of PDPN–
CD31– cells (which are heterogeneous and most likely include red 
pulp–derived fibroblasts). However, flow cytometry did not detect 
surface DLL4 in these latter cell types, a finding consistent with 
our observation of restricted expression of DLL4 in fibroblast sub-
sets of the white pulp.
Immunofluorescence microscopy of spleens from TgCcl19-Cre+ 
Dll1+/+ Dll4+/+ ROSA26eYFP and TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ ROSA26eYFP 
allo-BMT mice provided anatomical landmarks and demonstrat-
ed that, within white pulp areas, only a subset of Ccl19-Cre lin-
eage–traced eYFP+ cells expressed high levels of DLL4 protein. 
The coexpression of CD35 and CD157 and the organization in a 
follicular morphology point to FDC-like cells as being the highest 
expressors of DLL4. We observed loss of DLL4 expression in FDC-
like cells, identified as eYFP+CD35+ (Figure 8A), and in eYFP+ 
CD157+ cells (Figure 8B) from TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ ROSA26eYFP 
mice. Loss of DLL4 in FRCs could not be assessed histologically 
due to low signals but was supported by flow cytometric data (Sup-
plemental Figure 8C). To assess whether alloantigen-specific T 
cells first localized next to DLL4-expressing stromal cells in SLOs 
after allo-BMT, we injected CD4+ 4C T cell receptor–transgenic 
(TCR-transgenic) T cells specific to recipient I-Ad MHC class II and 
tracked these alloantigen-specific T cells during their early win-
dow of Notch sensitivity. Using EdU incorporation, we detected 
proliferating donor 4C T cells only within white pulp cords, close 
to both DLL4-expressing CD157+ and CD35+ fibroblastic stromal 
cells (Figure 8, C–E). Altogether, our data suggest that fibroblastic 
subsets of the white pulp cords form specialized niches that pro-
vide DLL4 Notch ligands to incoming T cells and promote their 
pathogenic properties at the onset of GVHD.
Discussion
Preclinical models identified donor and host hematopoietic APCs 
as critical cellular partners of donor T cells at the onset of GVHD 
(2, 5–7, 56). Early interactions between donor T cells and APCs, 
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gests that fibroblastic stromal cell subsets regulate specific aspects 
of immune cell biology through dedicated signaling pathways (e.g., 
Notch), consistent with the delivery of unique activation codes to 
immune cell subsets. Moreover, the post-transplantation envi-
ronment may enhance the delivery of Notch signals to incoming 
T cells through activation of fibroblastic stromal cells after irradi-
ation and loss of competing radiation-sensitive host lymphocytes.
The precise molecular mechanisms by which early Notch sig-
nals increase the pathogenicity of alloreactive T cells remain to be 
investigated further. We previously reported that Notch-deprived 
alloreactive T cells acquire a hyporesponsive phenotype with 
decreased TCR/CD28-mediated Ras/MAPK and NF-κB acti-
vation (65). As these changes were observed upon genetic inter-
ference with the Notch transcriptional activation complex (11, 
14, 65), the effects of Notch signaling in alloreactive T cells must 
ultimately be mediated by canonical transcriptional mechanisms. 
Our observations now provide insights into the critical early win-
dow of time during which alloantigen-specific T cells are exposed 
to essential Notch signals. Gene expression analysis revealed 
that only small numbers of known Notch transcriptional targets, 
including Dtx1, Hes1, Il2ra, and Trib2, were downregulated in this 
context. More work is necessary to establish whether the profound 
effects of Notch signaling in alloreactive T cells are accounted for 
by novel effects of these known Notch target genes, or by other 
previously unknown transcriptional targets that are controlled by 
Notch in mature T cells.
Our in vivo results contrast with those of past work identifying 
a role for stromal cells as negative regulators of immune responses 
(66–68), as the dominant role of these cells after allo-BMT was to 
promote rather than restrain alloimmune reactivity. In previous 
studies, the addition of ex vivo–isolated FRCs to T cell/DC cocul-
tures suppressed T cell proliferation in a dose-dependent fashion. 
Suppression was mediated by IFN-γ–dependent upregulation of 
NOS2 and COX1/2-dependent metabolites within FRCs. While 
Nos2 inactivation resulted in enhanced T cell proliferation in vivo, 
the lack of specificity of the genetic targeting strategy made it dif-
ficult to assess whether FRCs were in fact responsible for enforc-
ing this suppressive mechanism. Furthermore, the expression of 
Notch ligands on FRCs was not examined in these in vivo or in 
vitro studies. In our in vivo studies, irradiation of allo-BMT recip-
ients upregulated the expression of several surface markers on 
stromal cells, changed their morphology, and resulted in profound 
remodeling of SLO microanatomy within the first few days of 
transplantation. Thus, it is possible that the highly inflammatory 
environment that ensues after irradiation, in combination with the 
differences in the nature and availability of antigen, could account 
for the extreme proinflammatory functions of fibroblastic stromal 
cells after allo-BMT. It is also possible that alloreactive T cells gain 
unique access to fibroblastic niches from which T cells are typical-
ly excluded, such as FDCs or follicular FRCs residing in the outer 
B cell zone. Alternatively, our observations may reveal a previous-
ly unrecognized proinflammatory function of stromal cells medi-
ated by Notch signaling that also operates in other contexts.
With regard to a temporal requirement for Notch signaling, 
systemic delivery of DLL1/4-blocking antibodies at the time of 
transplantation had profound effects on T cell cytokine produc-
tion, Treg expansion, and overall T cell alloreactivity, but inhi-
of Notch ligands for marginal-zone B cells, ESAMhi DCs, and T 
follicular helper cells (32). During alloimmune responses, direct 
interaction of T cells with these defined stromal niches may deliv-
er important molecular cues in a temporally and spatially con-
trolled fashion. An in-depth characterization of the cellular and 
humoral signals delivered within these defined niches should pro-
vide additional critical insight into the molecular pathogenesis of 
GVHD. Furthermore, upstream signals and transcription factors 
controlling the expression of Delta-like Notch ligands and chemo-
kines in fibroblastic stromal cells remain to be discovered.
It is interesting to speculate as to why alloreactive T cells 
derive all their critical DLL1/4-mediated Notch signals from small 
subsets of fibroblastic cells, while Notch ligands are expressed by 
multiple other cell types in SLOs, including endothelial cells and 
hematopoietic cells. The precise pattern of alloreactive T cell traf-
ficking in SLOs may be important in explaining this phenomenon. 
We speculate that CCL19 and other chemokines such as CCL21 
and CXCL13 recruit incoming alloreactive T cells into specialized 
fibroblastic networks that resemble B and T zone niches, where 
T cells engage in durable interactions with fibroblastic cells that 
induce high-intensity Notch signals. Adhesion molecules and oth-
er concomitant signals may also play a role in T cell retention in 
this microenvironment. As only limited information is available to 
date about how alloantigen-specific T cells traffic in SLOs during 
their initial priming (59), additional investigations will be needed 
to address these questions.
Among fibroblastic stromal cells, FRCs support steady-state 
immune homeostasis through the secretion of IL-7, CCL19, and 
CCL21 (42, 60, 61). In vitro, FRCs enhance naive CD4+ or CD8+ 
T cell survival and viability in an IL-7/CCL19–dependent manner, 
while Ccl19 loss in vivo results in decreased total numbers of CD4+ 
and CD8+ T cells. Importantly, genetic Dll1/4 inactivation of Notch 
ligands with Ccl19-Cre did not negatively impact the ability of 
FRCs to maintain naive T cell homeostasis, as the total number of 
immune cells within LN and spleen and the distribution of naive/
memory cells at steady state were unaffected. Consistent with this 
notion, Il7 transcripts were unaltered in sort-purified FRCs from 
TgCcl19-Cre+ Dll1Δ/Δ Dll4Δ/Δ mice, showing that DLL1/4 loss did not 
globally disrupt FRC function.
FRCs can regulate immunity through multiple mechanisms. 
FRCs form a scaffold to which DCs can adhere and present anti-
gens to naive T cells, thus using the FRC network as a “road sys-
tem” for their migration (45, 47, 62). This random migration is 
enhanced by the chemokines CCL19 and CCL21, which are con-
stitutively expressed by FRCs. Physical removal of FRCs after SLO 
development prevents the efficient activation and proliferation 
of antigen-specific T cells (37, 63, 64). In contrast, in our studies, 
genetic Dll1/4 inactivation with Ccl19-Cre preserved T cell hom-
ing, as equivalent numbers of donor CD4+ and CD8+ T cells were 
isolated in SLOs. Furthermore, donor T cells upregulated the early 
activation markers CD69 and CD44 upon transfer into TgCcl19–Cre+ 
Dll1Δ/Δ Dll4Δ/Δ mice, suggesting their preserved ability to encounter 
and respond initially to alloantigens. Finally, donor T cells demon-
strated no obvious impairment in their ability to proliferate in 
response to antigen. Thus, our observations differ from the broader 
dysfunction of SLOs observed upon physical elimination of Ccl19-
Cre+ FRCs (37, 63, 64). Instead, our targeted genetic approach sug-
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hours prior to allo-BMT, while B6 mice received 2 doses of 6 Gy irradi-
ation (137Cs) separated by 3 hours. T cell–depleted BM (TCD BM) was 
prepared with anti-Thy1.2 antibodies and complement (Cedar Lane 
Laboratories) (14), resulting in over 95% depletion of Thy1.2+ cells. 
BALB/c recipients received 5 × 106 to 10 × 106 TCD BM ± 5 × 106 donor 
splenocytes, while B6 recipients received 10 × 106 to 15 × 106 TCD BM 
± 20 × 106 splenocytes. Clinical GVHD score and weight changes were 
monitored at least weekly, as described previously (11, 14, 15, 76).
Antibody-mediated inhibition of Delta-like Notch ligands. Human-
ized IgG1-neutralizing antibodies against DLL1, DLL4, and isotype 
control were described previously (14, 70, 77). All antibodies were 
injected i.p. (5 mg/kg twice weekly). The potency and specifici-
ty of each antibody batch was verified by assessing their capacity to 
achieve in vivo depletion of DLL1-dependent marginal-zone B cells or 
DLL4-dependent thymocytes (14, 24, 73).
Generation of BM hematopoietic chimeras and GVHD induction. 
B6-CD45.2 TgMx1-Cre+ Dll1fl/fl Dll4fl/fl donor mice or control littermates 
received 5 i.p. injections of 50 μg poly(I:C) (Amersham) every oth-
er day. Two weeks after the last poly(I:C) dose, six- to ten-week-old 
female B6-CD45.1 mice received 9 Gy of irradiation and were recon-
stituted with syngeneic BM from poly(I:C)-induced TgMx1-Cre+ Dll1Δ/Δ 
Dll4Δ/Δ mice or their control littermates. Donor chimerism was quan-
tified 12 weeks later by determining the relative frequency of CD45.2+ 
cells within mature cell populations in blood and spleen. The effi-
ciency of Cre-mediated Dll1 and Dll4 recombination was assessed by 
PCR in sort-purified blood myeloid cells using the following primers: 
Dll1 forward: CACACCTCCTACTTACCTGA; Dll1 reverse: GAGAG-
TACTGGATGGAGCAAG; Dll1 loxas: GGCGCTCAAAGGATATG-
GGA; Dll4 forward: GTGCTGGGACTGTAGCCACT; Dll4 reverse: 
TGTTAGGGATGTCGCTCTCC; and Dll4 revdel: CTCGTCTGTTC-
GCCAAATCTTAC. In other experiments, Notch2fl/fl mice were used 
to generate BM chimeras with poly(I:C)-induced TgMx1-Cre+ Notch2Δ/Δ or 
control TgMx1-Cre– Notch2fl/fl donor BM (75).
BM chimeras were rested at least 12 weeks to allow for establish-
ment of steady-state hematopoiesis before GVHD induction. BM chi-
meras were irradiated with 2 doses of 5.5 Gy each (137Cs), separated 
by 3 hours, and received 8 × 106 TCD BM ± 30 × 106 splenocytes from 
BALB/c donors (or syngeneic B6 donors as a negative control). Clinical 
GVHD score and weight changes were monitored at least weekly (11, 
14, 15). For Notch2Δ/Δ or Notch2+/+ BM chimeras, transplantation was 
performed with 107 BALB/c BM and 5 × 106 T cells (Thy1 selection; 
EasySep; STEMCELL Technologies).
LN and splenic stromal cell isolation. Stromal cells were isolated 
from LNs using a modified version of a previously described proto-
col (32, 42). Briefly, peripheral LNs (cervical, axial, brachial, ingui-
nal) from unirradiated or irradiated mice were coarsely chopped 
with a scalpel and incubated at 37°C for 15 minutes in digestion solu-
tion containing DMEM, 2% FBS, 1.2 mM CaCl2, penicillin/strepto-
mycin, and 1.0 mg/ml collagenase IV (Invitrogen, Thermo Fisher 
Scientific) and 40 μg/ml DNAse I (Roche). Samples were pipetted 
gently and reincubated at 37°C until all solid material appeared to 
be dissolved. Suspensions were filtered through a 70-μM strainer 
and analyzed by flow cytometry. For spleen, chopped fragments 
were incubated at 37°C for 15 minutes with 1.0 mg/ml collagenase 
IV, 0.5 mg/ml collagenase D, 0.25 mg/ml dispase (Invitrogen, Ther-
mo Fisher Scientific), and 40 μg/ml DNAse I (Roche). Samples 
were pipetted and macroscopic components allowed to settle while 
bition delayed by only 2 days failed to efficiently block GVHD. 
This narrow window of therapeutic sensitivity is significant in 
terms of translational applications. Indeed, short-term DLL1/4 
inhibition during this critical time has emerged as an attractive 
therapeutic strategy for preventing GVHD without exposing 
recipients to the risks of long-term DLL1/4 blockade (69–71). 
Mechanistically, this narrow window might reflect the temporal 
delivery of a physical pulse of Notch signaling in defined micro-
anatomical niches after allo-BMT. This physical pulse may result 
from transient exposure to cellular sources of Notch ligands that 
are typically inaccessible to T cells, or from prolonged initial 
contacts with fibroblastic stromal cell subsets that upregulate 
DLL1/4. Alternatively, our findings could reflect the existence of 
a unique window of T cell sensitivity to Notch signaling during 
early stages of priming and activation.
Altogether, our study reveals for the first time to our knowl-
edge the existence of specialized subsets of host nonhematopoi-
etic fibroblastic cells that deliver Notch signals to donor T cells at 
early stages after allo-BMT to program the pathogenicity of these 
T cells. Donor and host hematopoietic APCs were dispensable 
sources of Notch ligands, thus challenging the widely accepted 
hypothesis that motile APCs simultaneously provide both anti-
gen and Notch ligands to prime T cells. These findings illustrate 
the importance of exploring Notch signaling in vivo using loss-of-
function approaches, as relevant sources of Notch ligands may be 
missing from established in vitro experimental systems. Our work 
also highlights the utility of precisely targeting immunomodula-
tory pathways in stromal cells, as we uncovered what we believe 
to be a previously unrecognized pathogenic role for fibroblastic 
stromal cells independent of their functions in structural integrity 
and immune homeostasis. In GVHD, allograft rejection, and other 
immune disorders, we believe our findings pave the way toward 
selective inhibition of niche-derived signals that drive deleteri-
ous immune responses, without interfering with other essential 
immunological functions of the lymphoid environment.
Methods
Mice. BALB/c (H-2d), C57BL/6 (H-2b, CD45.2) (B6), and B6-CD45.1 
(H-2b, CD45.1) mice were bred at the University of Michigan. TgMx1-Cre, 
Dll1fl/fl, Dll4fl/fl, Notch2fl/fl, and 4C Rag1–/– TCR–transgenic mice were 
previously described (24, 72–75). TgMx1-Cre allows for IFN-inducible acti-
vation of Cre expression, e.g., via systemic administration of poly(I:C). 
4C Rag1–/– mice have a monoclonal population of CD4+ T cells specific 
for I-Ad MHC class II alloantigens, which enables tracking of alloanti-
gen-specific T cells in vivo (72). TgMx1-Cre Dll1fl/fl Dll4fl/fl mice were main-
tained on the B6 background and were backcrossed onto the BALB/c 
background for more than 5 generations. Ccl19-Cre BAC–transgenic 
mice (TgCcl19-Cre) express Cre recombinase in subsets of nonhemato-
poietic stromal cells under the control of a 90-kb regulatory sequence 
upstream of the Ccl19 transcriptional start site (32, 36–38). TgCcl19-Cre 
mice were crossed with B6 Dll4fl/fl Dll1fl/fl ROSA26eYFP mice (expressing 
Cre-inducible eYFP under control of the ROSA26 promoter).
Induction and assessment of GVHD. Six- to ten-week-old BALB/c 
mice or eight- to twelve-week-old B6 recipients underwent allo-BMT 
as previously described (11, 14, 15). Both female and male mice were 
used as recipients and were distributed equally among experimental 
groups. BALB/c mice received 8.5–9 Gy irradiation (137Cs source) 4 
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processed images were often simplified into 2 color images with the 
ImageJ (NIH) “split channels” and “merge channels” functions.
EdU incorporation and detection. Mice were injected i.p. with 2.5 
mg/ml 5-ethynyl-2′-deoxyuridine (EdU) 12 hours prior to tissue col-
lection. LNs and spleens were fixed in 1% PFA for 2 hours, sunk in 30% 
sucrose overnight, and embedded and frozen in Tissue-Tek (Sakura 
Finetek) in an ethanol–dry ice bath. EdU was detected with a Click-iT 
EdU Alexa Fluor 488 Imaging Kit (Molecular Probes, Thermo Fisher 
Scientific) according to the manufacturer’s instructions.
Quantitative real-time PCR. Donor T cells or host stromal cells 
were sort purified directly into TRIzol Reagent (Invitrogen, Thermo 
Fisher Scientific). Total RNA was extracted with phenol/chloroform 
and purified with an RNeasy Micro Kit (QIAGEN). cDNA was gener-
ated with SuperScript II (Invitrogen, Thermo Fisher Scientific) and 
subjected to quantitative PCR with either TaqMan or SYBR Green 
PCR Master Mixes on an Eppendorf Mastercycler ep realplex (Applied 
Biosystems, Thermo Fisher Scientific). Gene expression analysis was 
performed using the following primers: Dtx1 (Mm00492297_m1, 
Applied Biosystems); Hes1 (Mm01342805_m1); Il2ra (Mm01340213_
m1); Pten (Mm00477209_m1); Trib2 (Mm00454876_m1); Il7 forward: 
GTGCCACATTAAAGACAAAGAAG; Il7 reverse: GTTCATTATTC-
GGGCAATTACTATC; Myc forward: CAGCGACTCTGAAGAAGAG-
CAAG; Myc reverse: GGGTTTGCCTCTTCTCCACAG; Hprt forward: 
CTCCTCAGACCGCTTTTTGC; and Hprt reverse: TAACCTG-
GTTCATCATCGCTAATC. Relative gene expression was determined 
using the ΔΔCt method, with normalization to Hprt.
Statistics. The sample size for in vivo mouse experiments was 
determined empirically on the basis of prior experience and used to 
calculate power with the “pwr” statistical package in R. Unless oth-
erwise noted, all statistical tests were done using Prism software 
(GraphPad Prism7). Briefly, the means of 2 different groups were com-
pared with an unpaired, 2-tailed Student’s t test. If the variances of 2 
groups differed significantly by F test, a Welch’s correction for t tests 
was used. If multiple t tests were evaluated at once within a data set, 
the Holm-Sidak method was used to adjust for multiple comparisons, 
assuming α = 0.05. Survival curves were compared using a log-rank 
(Mantel-Cox) test. Bar graphs were generated with GraphPad Prism.
Study approval. All experiments were performed according to NIH 
guidelines and approved by the Committee on the Use and Care of 
Animals of the University of Michigan.
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supernatant was filtered, washed, and resuspended in PBS and 2% 
FBS. The remaining solid components were subjected to sequential 
rounds of digestion, pipetting, and collection of supernatant until 
no macroscopic components remained.
Flow cytometric analysis. The following antibodies were from 
BioLegend: CD4 (clone GK1.5); CD8α (clone 53-6.7); CD19 (clone 
6D5); CD11c (clone N418); CD11b (clone M1/70); F4/80 (clone 
BM8); PDCA1 (clone 129C1); B220 (clone RA3-6B2); MHC II (clone 
M5/114.15.2); CD44 (clone IM7); CD62L (clone MEL-14); PDPN/gp38 
(clone 8.1.1); CD31 (clone 390); Ter119 (clone TER-119); CD157 (clone 
BP-3); CD25 (clone PC61); CD21/35 (clone 7E9); CD45 (clone 30-F11); 
TCRβ (clone Η57-597); H-2Kb (clone AF6-88.5); H-2Kd (clone SF1-1.1); 
IFN-γ (clone XMG1.2); TNF-α (clone MP6-XT22); and IL-2 (clone 
JES6-5H4). Anti-FoxP3 (clone FJK-16s) and anti-CD207/anti-langerin 
(clone eBioL31) antibodies were from eBioscience. For flow cytomet-
ric analysis of DLL4 surface expression, samples were blocked in rat/
mouse serum on ice for 15 minutes, stained on ice with biotinylated 
anti-DLL4 (clone 9A1.5; a gift of H.R. McDonald, Ludwig Institute for 
Cancer Research, Lausanne, Switzerland) (78) for 1 hour in NaN3 and 
EDTA-free FACS buffer, stained with surface markers for 30 minutes 
on ice, washed twice, and stained in streptavidin-allophycocyanin 
(streptavidin-APC) (1:100) for 30 minutes on ice. For assessment of 
T cell cytokine production, donor splenocytes were stimulated with 
plate-bound anti-CD3 (2.5 μg/ml; clone 145-2C11; BD Biosciences) 
and anti-CD28 (2.5 μg/ml; clone 37.51; BD Biosciences) for 2 to 3 hours 
prior to the addition of monensin (GolgiStop; BD Biosciences). Sam-
ples were fixed and stained for intracellular proteins according to the 
manufacturer’s instructions. Flow cytometric analysis was performed 
on a 3-laser Fortessa or 4-laser FACSAria II/III (both from BD). Dead 
cells were excluded with DAPI (Sigma-Aldrich) or Zombie Aqua Fix-
able Viability Dye (BioLegend).
Immunofluorescence microscopy. LNs and spleens were fixed in 1% 
PFA for 2 hours, sunk in 30% sucrose overnight, and embedded and 
frozen in Tissue-Tek O.C.T. (Sakura Finetek) in an ethanol–dry ice 
bath. Staining of 6- to 8-μm-thin cryosections was performed for 60 
minutes or overnight at room temperature using the following anti-
bodies: monoclonal anti-CD3ε (145-2C11); B220 (RA3-6B2); CD35 
(8C12); PDPN/gp38 (8.1.1); MAdCAM-1 (Meca-89); (all purified in 
house at the Institute of Biochemistry, University of Lausanne, Lau-
sanne, Switzerland); and polyclonal goat anti-DLL4 (AF1389; R&D 
Systems). The following secondary antibodies were used: donkey 
anti–rat biotin; donkey anti–rat Cy3; donkey anti–rabbit Cy3; donkey 
anti–sheep APC (all from Jackson ImmunoResearch); and streptavidin 
Alexa Fluor 488 and donkey anti–rabbit Alexa Fluor 647 (both from 
Invitrogen, Thermo Fisher Scientific). For DLL4 labeling, primary 
antibodies were detected using a biotinylated donkey anti–goat IgG 
followed by HRP-coupled streptavidin (Jackson ImmunoResearch) 
and tyramide signal amplification (Invitrogen, Thermo Fisher Scien-
tific) according to the manufacturer’s instructions, but using a borate 
buffer (0.1 M in PBS, pH 8.5) for tyramide dilution. eYFP was detected 
using a rabbit anti-GFP antibody followed by Alexa Fluor 488–conju-
gated donkey anti–rabbit IgG (both from Invitrogen, Thermo Fisher 
Scientific). Images were acquired on an AxioImager.Z1 microscope 
with an AxioCam and were processed in Adobe Photoshop. Specifical-
ly, image contrast was adjusted using the “levels” tool, while image 
sharpness was improved with the “unsharpen mask” command. 
Tissue sections were stained with 3 different fluorochromes, but 
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